arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Biohaven Ltd.

BHVN Health Care Biotechnology: Pharmaceutical Preparations
$16.00
▲ +2.0% Today
as of Sep 4, 16:46 ET
Last 30 days +13.94% Jul 28 → Sep 04
$13.08 $14.12 $15.16 $16.20 $17.24 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$15.52
High
$15.80
Low
$15.21
Volume
$2M
Avg Vol
$3M
Mkt Cap
$2.0B
P/E (TTM)
—
Beta
—
52w High
$18.57
52w Low
$7.48
Div Yield
—
Shares Out
$151M

Recent Press Releases & News last 60 days · 25 items

Sep 3 · 11:59 Insider Monkey
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
Aug 28 · 07:32 Motley Fool
Why Biohaven Stock Was Rocking the Market This Week
Aug 27 · 14:40 Pharmaceutical Technology
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$7.48
$19
77% of range
Avg surprise (last 3)
-10.8%
Avg reaction (last 2)
+3.4%
100% positive
Latest IV / EM
71%
EM ±11.2% · $16 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-3.64$-2.95$-2.25$-1.56$-0.86 Actual $-1.03Actual $-1.32Actual $-1.50Actual $-2.20Actual $-3.64Actual $-1.70Actual $-2.17Est $-1.67Actual $-1.94Est $-1.94Actual $-1.64Actual $-0.88Est $-0.86Actual $-0.91 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-222M$-201M$-179M$-158M$-137M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.91 — — — — financials
Mon May 4, 2026Mar/2026 $-0.88 $-0.86 -2.3% +59.5% +5.3% earnings
Tue Sep 30, 2025Sep 2025 $-1.64 — — — — financials
Mon Aug 11, 2025Jun/2025 $-1.94 $-1.94 0.0% — — earnings
Mon May 12, 2025Mar/2025 $-2.17 $-1.67 -29.9% — +1.6% earnings
Mon Sep 30, 2024Sep 2024 $-1.70 — — — — financials
Sun Jun 30, 2024Jun 2024 $-3.64 — — — — financials
Sun Mar 31, 2024Mar 2024 $-2.20 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.50 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.32 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.03 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-125M$-130M—$-169M$-212M$-222M—$-178M
Net income$-137M$-131M—$-173M$-198M$-222M—$-160M
EPS (diluted)$-0.91$-0.88—$-1.64$-1.94$-2.17—$-1.70

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$238M$273M$230M$185M$166M$98M$99M$84M
Inventory————————
Total current assets$297M$386M$368M$324M$475M$383M$538M$440M
Total assets$371M$466M$451M$409M$550M$459M$615M$511M
Long-term debt————————
Total liabilities$359M$337M$399M$426M$416M$199M$192M$195M
Total equity$12M$130M$52M$-17M$135M$259M$423M$316M

Implied volatility — last 90 days

54%97%140%183%226% Jun 07 — IV 114% · EM ±15.7%Jun 08 — IV 107% · EM ±14.1%Jun 09 — IV 112% · EM ±14.0%Jun 10 — IV 96% · EM ±11.3%Jun 11 — IV 113% · EM ±12.5%Jun 12 — IV 156% · EM ±16.0%Jun 15 — IV 127% · EM ±9.2%Jun 16 — IV 126% · EM ±7.4%Jun 17 — IV 227% · EM ±9.5%Jun 19 — IV 93% · EM ±20.4%Jun 22 — IV 101% · EM ±21.2%Jun 23 — IV 92% · EM ±18.9%Jun 24 — IV 91% · EM ±18.2%Jun 25 — IV 97% · EM ±18.9%Jun 26 — IV 87% · EM ±16.7%Jun 29 — IV 95% · EM ±16.9%Jun 30 — IV 90% · EM ±15.5%Jul 01 — IV 87% · EM ±14.6%Jul 02 — IV 83% · EM ±13.4%Jul 03 — IV 84% · EM ±13.2%Jul 06 — IV 97% · EM ±13.4%Jul 07 — IV 91% · EM ±12.1%Jul 08 — IV 104% · EM ±13.1%Jul 09 — IV 125% · EM ±14.7%Jul 10 — IV 95% · EM ±10.4%Jul 13 — IV 112% · EM ±9.4%Jul 14 — IV 153% · EM ±11.0%Jul 15 — IV 105% · EM ±6.2%Jul 16 — IV 169% · EM ±7.1%Jul 20 — IV 90% · EM ±21.3%Jul 21 — IV 82% · EM ±19.2%Jul 22 — IV 76% · EM ±17.3%Jul 23 — IV 90% · EM ±20.1%Jul 24 — IV 85% · EM ±18.7%Jul 27 — IV 70% · EM ±14.6%Jul 28 — IV 90% · EM ±18.3%Jul 30 — IV 99% · EM ±19.4%Jul 31 — IV 87% · EM ±16.7%Aug 03 — IV 90% · EM ±15.9%Aug 04 — IV 91% · EM ±15.6%Aug 05 — IV 97% · EM ±16.1%Aug 06 — IV 106% · EM ±17.2%Aug 07 — IV 124% · EM ±19.4%Aug 10 — IV 105% · EM ±14.5%Aug 11 — IV 65% · EM ±8.6%Aug 12 — IV 73% · EM ±9.2%Aug 13 — IV 84% · EM ±9.9%Aug 14 — IV 79% · EM ±8.7%Aug 17 — IV 101% · EM ±8.5%Aug 18 — IV 82% · EM ±5.9%Aug 19 — IV 138% · EM ±8.1%Aug 20 — IV 222% · EM ±9.3%Aug 24 — IV 80% · EM ±16.6%Aug 25 — IV 79% · EM ±16.2%Aug 26 — IV 79% · EM ±15.8%Aug 27 — IV 55% · EM ±10.7%Aug 28 — IV 58% · EM ±11.0%Aug 31 — IV 68% · EM ±12.1%Sep 01 — IV 77% · EM ±13.2%Sep 02 — IV 71% · EM ±11.8%Sep 03 — IV 77% · EM ±12.5%Sep 04 — IV 71% · EM ±11.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in